Saturday 17 October 2026
Export LUCD’s income statement to Excel — free account
Lucid Diagnostics Inc.
LUCD Healthcare Medical Devices
Lucid Diagnostics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 million, up 8.28% from fiscal 2024. In the quarter to June 2026, revenue grew 26.7%, EPS was flat, free cash flow fell 7.04% and total debt fell 7.11%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
0.48
0.04
−7.69%
Follow LUCD
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
35.99 | 31.38 | 23.61 | 24.84 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(17.34) | (13.31) | (8.83) | (10.03) | |
P/B ratio |
17.93 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
18.11 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
34.17 | 30.86 | 21.34 | 19.15 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.97) | (3.44) | (2.16) | (1.92) | |
EV/FCF |
(3.94) | (3.41) | (2.15) | (1.91) | |
Quick Ratio |
1.25 | 0.97 | 1.24 | 1.83 | |
Current Ratio |
1.33 | 1.07 | 1.31 | 1.90 | |
Net Debt/EBITDA |
0.79 | 0.23 | 0.78 | 2.17 | |
Debt/Assets |
60.34% | 73.94% | 59.34% | 41.92% | |
Debt/Equity |
2.15 | 6.30 | 2.19 | 0.86 | |
Asset Turnover |
0.14 | 0.15 | 0.13 | 0.12 | |
Operating CF/Net income |
0.77 | 0.51 | 0.77 | 1.05 | |
Capex/Depreciation |
(0.09) | (0.97) | (0.24) | (0.13) | |
Interest Coverage |
(3,200.25) | (2,019.00) | (2,802.00) | (5,879.50) | |
Research and Development Expense of Revenue |
80.87% | 96.02% | 114.56% | 105.04% | |
Selling, General and Administrative Expense of Revenue |
782.43% | 830.73% | 786.30% | 817.18% | |
Intangible Assets out of Total Assets |
0.00 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
114.86% | 112.34% | 77.46% | 95.13% | |
Graham Net Nets |
0.04 | 0.01 | 0.07 | 0.21 | |
Graham Number |
0.00 | 0.68 | 3.03 | 2.48 | |
Earnings Yield |
(43.93%) | (40.87%) | (88.07%) | (102.97%) | |
Free Cash Flow Yield |
(24.08%) | (28.82%) | (42.01%) | (40.44%) | |
Revenue per Share |
0.01 | 0.01 | 0.01 | 0.01 | |
Operating CF per Share |
(0.06) | (0.09) | (0.12) | (0.10) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.06) | (0.09) | (0.12) | (0.10) | |
Cash per Share |
0.18 | 0.20 | 0.34 | 0.44 | |
Shareholders Equity per Share |
0.06 | 0.03 | 0.11 | 0.24 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.06 | 0.03 | 0.11 | 0.24 | |
Free Cash Flow |
(11.32) | (12.32) | (12.63) | (10.92) | |
Working Capital |
9.11 | 1.98 | 8.89 | 23.64 | |
Capital Expenditures |
(0.02) | (0.21) | (0.05) | (0.03) | |
Net Current Asset Value |
8.60 | 1.28 | 7.96 | 22.48 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.17 | 0.03 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.73 | 0.38 | 0.34 | 0.29 | |
Average Payables |
0.75 | 0.95 | 1.11 | 0.94 | |
Average Inventory |
0.49 | 0.48 | 0.35 | 0.57 | |
Average Assets |
38.81 | 33.44 | 35.58 | 37.90 | |
Average Common Equity |
(17.81) | (32.96) | (46.18) | (39.01) |
Columns are period end dates